MapLight Therapeutics, Inc.

NasdaqGS:MPLT Stock Report

Market Cap: US$1.8b

MapLight Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:MPLT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Apr 26SellUS$521,146Christopher KroegerIndividual19,187US$27.49
16 Apr 26SellUS$78,572Vishwas SetiaIndividual2,922US$27.49
16 Apr 26SellUS$49,134Kristopher HansonIndividual1,827US$27.49
16 Apr 26SellUS$86,859Erin FoffIndividual3,213US$27.49
16 Apr 26SellUS$122,574James LillieIndividual4,513US$27.49
15 Apr 26SellUS$95,530Jonathan GillisIndividual3,590US$26.61
15 Apr 26SellUS$88,239Anatol KreitzerIndividual3,316US$26.61
24 Feb 26SellUS$260,398Robert MalenkaIndividual14,195US$19.06
20 Feb 26BuyUS$441,168George PavlovIndividual25,000US$17.86
13 Feb 26SellUS$220,632Robert MalenkaIndividual12,116US$18.21
11 Feb 26SellUS$124,329Robert MalenkaIndividual6,863US$18.12
10 Feb 26BuyUS$252,678Timothy GarnettIndividual14,124US$17.89
03 Feb 26SellUS$126,861Robert MalenkaIndividual7,040US$18.02
30 Jan 26SellUS$635,857Robert MalenkaIndividual34,398US$19.05
28 Oct 25BuyUS$92,499,992Catalyst4, IncCompany5,441,176US$17.00
28 Oct 25BuyUS$16,199,997Novo Holdings A/SCompany952,941US$17.00

Insider Trading Volume

Insider Buying: MPLT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of MPLT?
Owner TypeNumber of SharesOwnership Percentage
Public Companies912,0411.97%
Individual Insiders1,749,6433.77%
VC/PE Firms6,913,02214.9%
Institutions17,089,48936.9%
Private Companies19,697,46442.5%

Dilution of Shares: MPLT only recently listed within the past 12 months

Top Shareholders

Top 25 shareholders own 94.9% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
43.4%
Catalyst4, Inc
19,697,464US$774.5m0%no data
8.13%
Novo Holdings A/S
3,686,622US$145.0m0%0.2%
7.17%
T. Rowe Price Group, Inc.
3,250,266US$127.8m16.1%0.01%
7.12%
Forbion Capital Partners B.V.
3,226,400US$126.9m0%15.88%
3.49%
Pivotal BioVenture Partners LLC
1,582,700US$62.2m0%15.2%
2.95%
BlackRock, Inc.
1,339,731US$52.7m22.3%no data
2.5%
The Goldman Sachs Group, Inc.
1,133,385US$44.6m5.16%0.01%
2.22%
CHI Advisors LLC
1,005,929US$39.6m208%13.17%
2.1%
5AM Venture Management, LLC
950,011US$37.4m0%9.4%
2.01%
Sanofi
912,041US$35.9m0%2.04%
1.9%
Goldman Sachs Asset Management, L.P.
861,488US$33.9m0.25%0.01%
1.59%
Vanguard Capital Management, LLC
719,820US$28.3m0%no data
1.09%
Velan Capital Partners LP
492,893US$19.4m-5.63%11.23%
1.06%
Geode Capital Management, LLC
481,201US$18.9m23.7%no data
0.99%
Artal Group S.A.
450,000US$17.7m0%0.26%
0.93%
Vestal Point Capital, LP
420,000US$16.5m9.09%0.4%
0.83%
ADAR1 Capital Management, LLC
374,909US$14.7m0%0.74%
0.8%
Baker Bros. Advisors LP
364,705US$14.3m0%0.07%
0.79%
Vishwas Setia
356,256US$14.0m1,040%no data
0.76%
Erin Foff
346,059US$13.6m-14.3%no data
0.75%
State Street Global Advisors, Inc.
339,116US$13.3m47.8%no data
0.69%
Freestone Grove Partners LP
313,957US$12.3m70.8%0.08%
0.55%
RA Capital Management, L.P.
248,294US$9.8m0%0.1%
0.54%
James Lillie
242,729US$9.5m157%no data
0.52%
UBS Asset Management AG
236,512US$9.3m1,190%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 21:38
End of Day Share Price 2026/07/13 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MapLight Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sumant Satchidanand KulkarniCanaccord Genuity
Adam VogelCraig-Hallum Capital Group LLC
Raghuram SelvarajuH.C. Wainwright & Co.